REPURPOSING OF DRUGS: EMERGING SCENARIO


Abstract views: 48 / PDF downloads: 8

Authors

  • T. Jagadeesh Department of Veterinary Pharmacology and Toxicology Madras Veterinary College, Chennai- 600 007, Tamil Nadu
  • G. Sathish Ph.D. Scholar, Department of Animal Biotechnology, Madras Veterinary College, TANUVAS, Chennai- 600 007
  • M. Parthiban Professor, Department of Animal Biotechnology, Madras Veterinary College, TANUVAS, Chennai - 7
  • P. Raja Assistant Professor, Department of Animal Biotechnology, Madras Veterinary College, TANUVAS, Chennai –7
  • G. Sarathchandra Professor and Head, Pharmacovigilance Laboratory for Animal Feed and Food Safety, TANUVAS, Madhavaram Milk Colony, Chennai- 600 051

Keywords:

Drug repurposing, Anti-parasitic drugs, Anti-neoplastic drugs, COVID-19, Antihypertensive drugs, Antidiabetic drugs, In silico technique, Research and Development

Abstract

In recent times drug repurposing has gained interest over the traditional drug discovery due to reduction in time and cost of development of new drug. Drug repurposing approach has given promising drug candidates for various viral diseases like COVID 19, Ebola, Zika, Dengue, Influenza, HIV, Herpes, etc. Ontarget and off-target are the two basic strategies of drug repurposing. Macrolide, Artemisinin, Quinoline antiparasitic drugs are some of the drugs repurposed against cancer and drugs like thalidomide are repurposed against COVID-19 infection. Repurposing of veterinary drugs like ivermectin, levamisole and benzemidazole group of antiparasitic drugs are also under consideration. This review elaborates repurposing of antihypertensive drugs like angiotensin- converting enzyme inhibitors (ACEI), angiotensin-receptor blockers (ARBs), β-blockers as anti- neoplastic drugs, anti-diabetic drugs against Alzheimer’s disease, fluorophenyl benzimidazole (FPD) as antihypertensive drug, thalidomide against COVID-19 infection, levamisole as antineoplastic drug, benzimidazole as anti-cryptococcal drug and some other new drugs. Usage of in silico techniques and pharmacophore modeling strategies can further accelerate the process of drug repurposing. The drug repurposing strategies significantly minimize research and development costs, provide greater chances of success, shorter research time and lower investment risk. 

References

Abdel Khalek, A. and Seleem, M.N. (2020). Repurposing the veterinary antiprotozoal drug Ronidazole for the treatment of Clostridioides difficile Infection. International Journal of Antimicrobial Agents, 56(6): 106-188.

Agrawal, P. (2018). Artificial intelligence in drug discovery and development. Journal of Pharmacovigilance, 6(2): 1000e173.

Ashburn, T.T. and Thor, K.B. (2014). Drug repositioning: Identifying and developing new uses for existing drugs. Nature Reviews Drug Discovery, 3(8): 673-683.

Banchereau, J. and Steinman, R.M. (1998). Dendritic cells and the control of immunity. Nature, 392(6673): 245–252.

Baron, S.A., Devaux, C., Colson, P., Raoult, D. and Rolain, J.M. (2020). Teicoplanin: an alternative drug for the treatment of COVID-19? International Journal of Antimicrobial Agents, 55(4): 105944.

Bonanni, L. and DallaVestra, M. (2012). Oral renin inhibitors in clinical practice: a perspective review. Therapeutic Advances in Chronic Disease, 3(4): 173-181.

Cadegiani, F.A., Wambier, C.G. and Goren, A. (2020). Spironolactone: an antiandrogenic and anti-hypertensive drug that may provide protection against the novel coronavirus (SARS-CoV-2) induced acute respiratory distress syndrome (ARDS) in COVID-19. Frontiers in Medicine, 7: 453.

Cella, M., Sallusto, F. and Lanzavecchia, A. (1997). Origin, maturation and antigen presenting function of dendritic cells. Current Opinion in Immunology, 9(1): 10-16.

Chong, C.R. and Sullivan, D.J. (2007). New uses for old drugs, Nature, 448(7154): 645-646.

Collinsworth, K.A., Kalman, S.M. and Harrison, D.C. (1974). The clinical pharmacology of lidocaine as an antiarrhythmic drug. Circulation, 50(6): 1217-1230.

Cross, K.M., Landis, D.M., Sehgal, L. and Payne, J.D. (2021). Melatonin for the Early Treatment of COVID-19: A Narrative Review of Current Evidence and Possible Efficacy. Endocrine Practice, 27(8): 850-855.

De Luca, G., Cavalli, G., Campochiaro, C., Della-Torre, E., Angelillo, P., Tomelleri, A. Boffini, N., Tentori, S., Mette, F., Farina, N. and RovereQuerini, P. (2020). GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study. The Lancet Rheumatology, 2(8): e465-e473.

De Oliveira, H.C. and Rodrigues, M.L. (2021). Repurposing benzimidazoles to fight Cryptococcus. Fungal Biology Reviews, 37: 27-40.

Dey, G. (2019). An overview of drug repurposing: Review article. Journal of Medical Science and Clinical Research, 7(2): 3-5.

Dezong, G., Zhongbing, M., Qinye, F. and Zhigang, Y. (2014). Carvedilol suppresses migration and invasion of malignant breast cells by inactivating Src involving cAMP/PKA and PKCδ signaling pathway. Journal of Cancer Research and Therapeutics, 10(4): 991.

Etewa, S.E., El-Maaty, D.A.A., Hamza, R.S., Metwaly, A.S., Sarhan, M.H., AbdelRahman, S.A., Fathy, G.M. and ElShafey, M.A. (2018). Assessment of spiramycin-loaded chitosan nanoparticles treatment on acute and chronic toxoplasmosis in mice. Journal of Parasitic Diseases, 42(1): 102-113.

Ferrario, C.M., Trask, A.J. and Jessup, J.A. (2005). Advances in biochemical and functional roles of angiotensin converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function. American Journal of Physiology-Heart and Circulatory Physiology, 289(6): H2281-H2290.

Friis, T., Engel, A.M., Bendiksen, C.D., Larsen, L.S. and Houen, G. (2013). Influence of levamisole and other angiogenesis inhibitors on angiogenesis and endothelial cell morphology in vitro. Cancers, 5(3): 762-785.

Geary, T.G. (2005). Ivermectin 20 years on: maturation of a wonder drug. Trends in Parasitology, 21(11): 530-532.

Goldsmith, D.R. and Perry, C.M. (2004). Amphotericin B lipid complex: in visceral leishmaniasis. Drugs, 64(17): 1905-1911.

Haritha, C.V., Sharun, K. and Jose, B. (2020). Ebselen, a new candidate therapeutic against SARS-CoV-2. International Journal of Surgery (London, England), 84: 53.

Horby, P., Lim, W.S., Emberson, J.R., Mafham, M., Bell, J.L., Linsell, L., Staplin, N., Brightling, C., Ustianowski, A., Elmahi, E. and Prudon, B. (2021). Dexamethasone in Hospitalized Patients with Covid-19. New England Journal of Medicine, 384: 693-704.

Iqbal, H., Verma, A.K., Yadav, P., Alam, S., Shafiq, M., Mishra. Khan, F., Hanif, K., Negi, A.S. and Chanda, D. (2021). Antihypertensive effect of a novel angiotensin II receptor blocker fluorophenyl benzimidazole: contribution of cGMP, voltagedependent calcium channels, and BKCa channels to vasorelaxant mechanisms. Frontiers in Pharmacology, 12: 611109.

Kalita, J., Chetia, D. and Rudrapal, M. (2020). Design, synthesis, antimalarial activity, and docking study of 7-chloro-4-(2-(substituted benzylidene) hydrazineyl) quinolines. Medicinal Chemistry, 16(7): 928-937.

Khalil, A., Kamar, A. and Nemer, G. (2020). Thalidomide-revisited: are COVID-19 patients going to be the latest victims of yet another theoretical drug-repurposing? Frontiers in Immunology, 11: 1248.

Khalil, A., Tanos, R., El-Hachem, N., Kurban, M., Bouvagnet, P., Bitar, F. and Nemer, G. (2017). A Hand to TBX5 explains the link between thalidomide and cardiac diseases. Scientific Reports, 7(1): 1-13.

Lacey, E. (1988). The role of the cytoskeletal protein, tubulin, in the mode of action and mechanism of drug resistance to benzimidazoles. International Journal for Parasitology, 18(7): 885-936.

Li, J., Wang, W., Yao, J., Wang, T., Li, S., Qi, W., Han, S., Ren, Y., Dang, Z., Han, X. and Guo, G. (2020). Old drug repurposing for neglected disease: Pyronaridine as a promising candidate for the treatment of Echinococcus granulosus infections. EBio Medicine, 54: 102711.

Li, Y., Zheng, Q.Z., Liu, Q.X., Lu, X., Zhou, D., Zhang, J., Zheng, H. and Dai, J.G. (2021). Repositioning of antiparasitic drugs for tumor treatment. Frontiers in Oncology, 11: 670804.

López-Marure, R.A., Bernal, E. and Zentella, A. (1997). Interference with c-myc expression and RB phosphorylation during TNF-mediated growth arrest in human endothelial cells. Biochemical and Biophysical Research Communications, 236(3): 819-824.

Mahmoud, D.B., Shitu, Z. and Mostafa, A. (2020). Drug repurposing of nitazoxanide: can it be an effective therapy for COVID-19? Journal of Genetic Engineering and Biotechnology, 18(1): 35.

Mani, D., Wadhwani, A. and Krishnamurthy, P.T. (2019). Drug repurposing in antiviral research: a current scenario. Journal of Young Pharmacists, 11(2): 117.

Matthews, S.J. and McCoy, C. (2003). Thalidomide: a review of approved and investigational uses. Clinical Therapeutics, 25(2): 342-395.

Messerli, F.H., Bangalore, S., Bavishi, C. and Rimoldi, S.F. (2018). Angiotensin converting enzyme inhibitors in hypertension: to use or not to use? Journal of the American College of Cardiology, 71(13): 1474-1482.

Miglianico, M., Eldering, M., Slater, H., Ferguson, N., Ambrose, P., Lees, R.S., Koolen, K.M., Pruzinova, K., Jancarova, M., Volf, P. and Koenraadt, C.J. (2018). Repurposing isoxazoline veterinary drugs for control of vector- borne human diseases. Proceedings of the National Academy of Sciences, 115(29): E6920-E6926.

Miller, W.R., Bayer, A.S. and Arias, C.A. (2016). Mechanism of action and resistance to daptomycin in Staphylococcus aureus and enterococci. Cold Spring Harbor Perspectives in Medicine, 6(11): 026997.

Downloads

Submitted

21-08-2023

Published

13-09-2023

How to Cite

REPURPOSING OF DRUGS: EMERGING SCENARIO. (2023). Indian Journal of Veterinary and Animal Sciences Research, 52(3), 1-16. https://epubs.icar.org.in/index.php/IJVASR/article/view/141192